ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Celgene will pay Dragonfly Therapeutics $33 million up front as part of an immuno-oncology drug development pact. Celgene gains the right to license up to four blood cancer treatments developed using Dragonfly’s technology platform. Launched in 2015, Dragonfly is developing therapies that can link proteins expressed on the surface of cancer cells to white blood cells called natural killer cells, which then alert other immune cells to attack the cancer cells.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter